| Product Unit Size | Cost | Quantity | Stock |
|---|
Temozolomide is a second generation imidazotetrazine anticancer chemotherapeutic that is clinically approved to treat gliobastoma multiforme, anaplastic astrocytoma, and oligodendrocytoma. Temozolomide acts as an alkylating agent, attaching alkyl groups to guanine bases in DNA and interfering with DNA replication. This compound is 100% orally bioavailable and enters the cerebrospinal fluid easily and quickly.
| Cas No. | 85622-93-1 |
|---|---|
| Purity | ≥98% |
| Formula | C6H6N6O2 |
| Formula Wt. | 194.15 |
| Chemical Name | 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5- tetrazine-8-carboxamide |
| IUPAC Name | 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide |
| Synonym | Methazolastone, Temodal, Temodar |
| Melting Point | 212°C (dec) |
| Solubility | Soluble in DMSO to 39mg/mL, Water to 5 mg/mL, Ethanol <1mg/mL |
| Appearance | White to light pink powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Nagasawa DT, Chow F, Yew A, et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012 Apr;23(2):307-22, ix. PMID: 22440874.
Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010 Sep;31(8):1383-4. PMID: 2053882.
Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. PMID: 10914698.
Horing E, Harter PN, Seznec J, et al. The “go or grow” potential of gliomas is linked to the necropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathol. 2012 Jul;124(1):83-97. PMID: 22249620.
Momiyama M, Suetsugu A, Chishima T, et al. Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice. Anticancer Res. 2013 Jan;33(1):103-106. PMID: 23267133.